ArticleNature communications2022
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 71 citations in OpenAlex.
- Conformational free energy landscape of sorting signal peptides in complex with bacterial sortases.Biophysical journal · 2026Article
- Review
- Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human VProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Heterologous betacoronavirus spike immunization in nonhuman primates elicits cross-reactive antibodies that neutralize both sarbeco- and merbecoviruses.bioRxiv : the preprint server for biology · 2026Article
- TLR7/8 agonist 3M-052 formulated in micelles induces local type I IFN response and antiviral immunity in zebrafish larvae.Frontiers in immunology · 2026Article
- Construction of a localized immune nicheActa pharmaceutica Sinica. B · 2026Article
- Site-directed tyrosinase conjugation on engineered ferritin retains immune recognition.Scientific reports · 2025Article
- Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice.Science translational medicine · 2025Article
- Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.Journal of virology · 2025Article
- Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates.Science translational medicine · 2025Article
- Article
- Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines.bioRxiv : the preprint server for biology · 2025Article
- Generation of an inflammatory niche in a hydrogel depot through recruitment of key immune cells improves efficacy of mRNA vaccines.Science advances · 2025Article
- [Platform technologies in vaccine development].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Review
- Viral and immune profiles during the first wave of SARS-CoV-2 infection in hospitalized patients in Sardinia, Italy.Scientific reports · 2025Article
- The Role of Vitamins, Magnesium, and Trace Elements in COVID-19 Treatment and Post-COVID-19 Rehabilitation: An Updated Overview.Current medicinal chemistry · 2025Review
- Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals.Cell · 2024Article
- Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates.Nature immunology · 2024Article
- Beyond COVID-19: the promise of next-generation coronavirus vaccines.Npj viruses · 2024Review
- NK cells modulate in vivo control of SARS-CoV-2 replication and suppression of lung damage.PLoS pathogens · 2024Article
Corrections and comments
- Update of
Authors and funding
44 authors at 9 institutions in 1 country.
Dapeng LiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
David R MartinezDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID 0000-0002-2940-8961
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID 0000-0002-4760-4923
Haiyan ChenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Maggie BarrDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Laura L SutherlandDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Esther LeeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Dieter MielkeDepartment of Surgery, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID 0000-0003-2182-0510
Whitney EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Amanda NewmanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kevin W BockInfectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.ORCID 0000-0001-9454-0937
Mahnaz MinaiInfectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.
Bianca M NagataInfectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.
Matthew GagneVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.ORCID 0000-0001-5526-6162
Daniel C DouekVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.
C Todd DeMarcoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Thomas N DennyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Thomas H OguinDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Alecia BrownDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Wes RountreeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Yunfei WangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Katayoun MansouriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Robert J EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID 0000-0003-4446-1194
Guido FerrariDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Gregory D SempowskiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID 0000-0003-0391-6594
Amanda EatonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID 0000-0003-3064-2947
Juanjie TangDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Silver Spring, MD, 20871, USA.
Derek W CainDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Sampa SantraBeth Israel Deaconess Medical Center, Boston, MA, 02215, USA.ORCID 0000-0002-8796-1714
Norbert PardiDepartment of Microbiology, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Drew WeissmanDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Mark A TomaiCorporate Research Materials Lab, 3M Company, St Paul, MN, 55144, USA.
Christopher B FoxInfectious Disease Research Institute, Seattle, WA, 98104, USA.
Ian N MooreInfectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.
Hanne AndersenBIOQUAL, Rockville, MD, 20850, USA.ORCID 0000-0003-1103-9608
Mark G LewisBIOQUAL, Rockville, MD, 20850, USA.ORCID 0000-0001-7852-0135
Hana GoldingDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Silver Spring, MD, 20871, USA.
Robert SederVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.ORCID 0000-0003-3133-0849
Surender KhuranaDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Silver Spring, MD, 20871, USA.ORCID 0000-0002-0593-7965
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID 0000-0001-6827-8701
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA. kevin.saunders@duke.edu.ORCID 0000-0001-7399-7954
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA. barton.haynes@duke.edu.
Duke University · USNational Institutes of Health · USCenter for Biologics Evaluation and Research · USUniversity of North Carolina at Chapel Hill · USBioqual · USUniversity of Pennsylvania · US3M (United States) · USBeth Israel Deaconess Medical Center · USInfectious Disease Research Institute · US
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MProject 4: Computational panbetaCoV immunogen designP01AI158571 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2021 to 2023
$28.0MProject 2 - GMP Manufacturing of mRNA ImmunogensU19AI142596 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2024
$19.0MRegional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3MRegional Biocontainment Laboratories Facility and Building System Upgrades SupportG20AI167200 · NIAID · DUKE UNIVERSITY · PI STAATS, HERMAN F · 2021 to 2022
$6.6MNIAID NIH HHS G20 AI167200NIAID NIH HHS P01 AI158571NIAID NIH HHS U19 AI142596NIAID NIH HHS UC6 AI058607NIH HHS P51 OD011132
Abstract
Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that induced neutralizing antibodies against SARS-CoV-2 and pre-emergent sarbecoviruses and protected non-human primates (NHPs) from SARS-CoV-2 WA-1 infection. Here, we find the RBD-scNP induced neutralizing antibodies in NHPs against pseudoviruses of SARS-CoV and SARS-CoV-2 variants including 614G, Beta, Delta, Omicron BA.1, BA.2, BA.2.12.1, and BA.4/BA.5, and a designed variant with escape mutations, PMS20. Adjuvant studies demonstrate variant neutralization titers are highest with 3M-052-aqueous formulation (AF). Immunization twice with RBD-scNPs protect NHPs from SARS-CoV-2 WA-1, Beta, and Delta variant challenge, and protect mice from challenges of SARS-CoV-2 Beta variant and two other heterologous sarbecoviruses. These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect animals from multiple different SARS-related viruses. Such a vaccine could provide broad immunity to SARS-CoV-2 variants.
Indexed as
COVID-19NanoparticlesSevere acute respiratory syndrome-related coronavirusViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralFerritinsMiceMice, Inbred BALB CSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralFerritinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.